Other > Journal Blog
Lancet Global Health. 2017 November 10
Fotheringham C
Lancet Global Health. 2017 November 10
Journal Article > LetterFull Text
Lancet Global Health. 2014 August 19; Volume 2 (Issue 8); DOI:10.1016/S2214-109X(14)70252-9
Dorlo TPC, Balasegaram M
Lancet Global Health. 2014 August 19; Volume 2 (Issue 8); DOI:10.1016/S2214-109X(14)70252-9
Journal Article > ReviewFull Text
Lancet Global Health. 2021 May 1; Volume 9 (Issue 5); e681-e690.; DOI:10.1016/S2214-109X(20)30539-8
Park JS, Grais RF, Taljaard M, Nakimuli-Mpungu E, Jehan F, et al.
Lancet Global Health. 2021 May 1; Volume 9 (Issue 5); e681-e690.; DOI:10.1016/S2214-109X(20)30539-8
This paper shows the scale of global health research and the context in which we frame the subsequent papers in the Series. In this Series paper, we provide a historical perspective on clinical trial research by revisiting the 1948 streptomycin trial for pulmonary tuberculosis, which was the first documented randomised clinical trial in the English language, and we discuss its close connection with global health. We describe the current state of clinical trial research globally by providing an overview of clinical trials that have been registered in the WHO International Clinical Trial Registry since 2010. We discuss challenges with current trial planning and designs that are often used in clinical trial research undertaken in low-income and middle-income countries, as an overview of the global health trials landscape. Finally, we discuss the importance of collaborative work in global health research towards generating sustainable and culturally appropriate research environments.
Journal Article > LetterFull Text
Lancet Global Health. 2023 April 1; Volume 11 (Issue 4); e502.; DOI:10.1016/S2214-109X(23)00115-8
Huerga H, Gupta-Wright A, Muyindike WR, Hewison CCH, Casenghi M, et al.
Lancet Global Health. 2023 April 1; Volume 11 (Issue 4); e502.; DOI:10.1016/S2214-109X(23)00115-8
Journal Article > ResearchFull Text
Lancet Global Health. 2018 May 3; Volume 6 (Issue 6); DOI:10.1016/S2214-109X(18)30230-4
Camacho A, Bouhenia M, Alyusfi R, Alkohlani A, Naji MAM, et al.
Lancet Global Health. 2018 May 3; Volume 6 (Issue 6); DOI:10.1016/S2214-109X(18)30230-4
In war-torn Yemen, reports of confirmed cholera started in late September, 2016. The disease continues to plague Yemen today in what has become the largest documented cholera epidemic of modern times. We aimed to describe the key epidemiological features of this epidemic, including the drivers of cholera transmission during the outbreak.
Journal Article > CommentaryFull Text
Lancet Global Health. 2020 March 1; Volume 8 (Issue 3); DOI:10.1016/S2214-109X(20)30040-1
Boum Y II, Mburu Y
Lancet Global Health. 2020 March 1; Volume 8 (Issue 3); DOI:10.1016/S2214-109X(20)30040-1
Journal Article > CommentaryFull Text
Lancet Global Health. 2019 December 1; Volume 7 (Issue 12); e1585-e1586.; DOI:10.1016/S2214-109X(19)30452-8
Kadir A, Garcia DM, Romero F
Lancet Global Health. 2019 December 1; Volume 7 (Issue 12); e1585-e1586.; DOI:10.1016/S2214-109X(19)30452-8
Journal Article > CommentaryFull Text
Lancet Global Health. 2016 October 4; Volume 4 (Issue 10); e680-681.; DOI:10.1016/S2214-109X(16)30173-5
Stoett P, Daszak P, Romanelli C, Machalaba C, Behringer R, et al.
Lancet Global Health. 2016 October 4; Volume 4 (Issue 10); e680-681.; DOI:10.1016/S2214-109X(16)30173-5
Journal Article > LetterFull Text
Lancet Global Health. 2018 February 9; Volume 6 (Issue 3); DOI:10.1016/S2214-109X(18)30038-X
Haidar MK, Alayyan A, Farhat JB, Defourny I
Lancet Global Health. 2018 February 9; Volume 6 (Issue 3); DOI:10.1016/S2214-109X(18)30038-X
Journal Article > ResearchFull Text
Lancet Global Health. 2016 November 1; Volume 4 (Issue 11); e856-e863.; DOI:10.1016/S2214-109X(16)30211-X
Azman AS, Parker LA, Rumunu J, Tadesse F, Grandesso F, et al.
Lancet Global Health. 2016 November 1; Volume 4 (Issue 11); e856-e863.; DOI:10.1016/S2214-109X(16)30211-X
BACKGROUND
Oral cholera vaccines represent a new effective tool to fight cholera and are licensed as two-dose regimens with 2-4 weeks between doses. Evidence from previous studies suggests that a single dose of oral cholera vaccine might provide substantial direct protection against cholera. During a cholera outbreak in May, 2015, in Juba, South Sudan, the Ministry of Health, Médecins Sans Frontières, and partners engaged in the first field deployment of a single dose of oral cholera vaccine to enhance the outbreak response. We did a vaccine effectiveness study in conjunction with this large public health intervention.
METHODS
We did a case-cohort study, combining information on the vaccination status and disease outcomes from a random cohort recruited from throughout the city of Juba with that from all the cases detected. Eligible cases were those aged 1 year or older on the first day of the vaccination campaign who sought care for diarrhoea at all three cholera treatment centres and seven rehydration posts throughout Juba. Confirmed cases were suspected cases who tested positive to PCR for Vibrio cholerae O1. We estimated the short-term protection (direct and indirect) conferred by one dose of cholera vaccine (Shanchol, Shantha Biotechnics, Hyderabad, India).
FINDINGS
Between Aug 9, 2015, and Sept 29, 2015, we enrolled 87 individuals with suspected cholera, and an 898-person cohort from throughout Juba. Of the 87 individuals with suspected cholera, 34 were classified as cholera positive, 52 as cholera negative, and one had indeterminate results. Of the 858 cohort members who completed a follow-up visit, none developed clinical cholera during follow-up. The unadjusted single-dose vaccine effectiveness was 80·2% (95% CI 61·5-100·0) and after adjusting for potential confounders was 87·3% (70·2-100·0).
INTERPRETATION
One dose of Shanchol was effective in preventing medically attended cholera in this study. These results support the use of a single-dose strategy in outbreaks in similar epidemiological settings.
Oral cholera vaccines represent a new effective tool to fight cholera and are licensed as two-dose regimens with 2-4 weeks between doses. Evidence from previous studies suggests that a single dose of oral cholera vaccine might provide substantial direct protection against cholera. During a cholera outbreak in May, 2015, in Juba, South Sudan, the Ministry of Health, Médecins Sans Frontières, and partners engaged in the first field deployment of a single dose of oral cholera vaccine to enhance the outbreak response. We did a vaccine effectiveness study in conjunction with this large public health intervention.
METHODS
We did a case-cohort study, combining information on the vaccination status and disease outcomes from a random cohort recruited from throughout the city of Juba with that from all the cases detected. Eligible cases were those aged 1 year or older on the first day of the vaccination campaign who sought care for diarrhoea at all three cholera treatment centres and seven rehydration posts throughout Juba. Confirmed cases were suspected cases who tested positive to PCR for Vibrio cholerae O1. We estimated the short-term protection (direct and indirect) conferred by one dose of cholera vaccine (Shanchol, Shantha Biotechnics, Hyderabad, India).
FINDINGS
Between Aug 9, 2015, and Sept 29, 2015, we enrolled 87 individuals with suspected cholera, and an 898-person cohort from throughout Juba. Of the 87 individuals with suspected cholera, 34 were classified as cholera positive, 52 as cholera negative, and one had indeterminate results. Of the 858 cohort members who completed a follow-up visit, none developed clinical cholera during follow-up. The unadjusted single-dose vaccine effectiveness was 80·2% (95% CI 61·5-100·0) and after adjusting for potential confounders was 87·3% (70·2-100·0).
INTERPRETATION
One dose of Shanchol was effective in preventing medically attended cholera in this study. These results support the use of a single-dose strategy in outbreaks in similar epidemiological settings.